The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing
The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) is a study to discover which biomarkers, cognitive characteristics, and health and lifestyle factors determine subsequent development of symptomatic Alzheimer’s Disease (AD).
A collaboration between CSIRO, the National Ageing Research Institute, Austin Health, Edith Cowan University and the Mental Health Research Institute, are working together to identify those at risk for AD and hope to develop blood-based screening approaches, as well as interventions to delay disease onset.
AIBL research to date shows disease progresses up to 20 years before clinical symptoms develop. Blood and imaging biomarkers identifying people at risk have been discovered that indicate that essential early screening for disease risk may be possible. Lifestyle patterns offering potential to delay disease onset are being investigated. Importantly, AIBL data is now being accessed worldwide with industry and academic researchers in order to improve understanding of the disease, inform early detection and potential interventions.
For further information please contact: Jurgen.Fripp@csiro.au